A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...
Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
The global photovoltaic (PV) industry is entering a phase defined less by headline capacity additions and more by incremental but compounding improvements in efficiency, reliability, and ...
Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to ...
Whether for drug screening or toxicity testing, stem cell-based 3D tissue models are key to biomedical research. However, ...
Manufacturing cell and gene therapies at hospitals in dedicated, GMP-accredited facilities would overcome many of the technical and logistical challenges associated with decentralized production. So ...
Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results